Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash from Financing Activities (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Cash from Financing Activities data on record, last reported at $124000.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 94.92% year-over-year to $124000.0; the TTM value through Sep 2025 reached $52.0 million, up 1636.01%, while the annual FY2024 figure was $53.7 million, 6797.3% up from the prior year.
  • Cash from Financing Activities reached $124000.0 in Q3 2025 per SNTI's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $232.0 million in Q2 2021 and bottomed at -$485000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $54.4 million, with a median of $716000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: plummeted 100.21% in 2022, then surged 10708.7% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $232.0 million in 2021, then tumbled by 99.62% to $876000.0 in 2022, then plummeted by 36.53% to $556000.0 in 2023, then skyrocketed by 9124.82% to $51.3 million in 2024, then plummeted by 99.76% to $124000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $124000.0 in Q3 2025, $1.0 million in Q2 2025, and -$414000.0 in Q1 2025.